Plan sponsors judge drug plans on cost, not health outcomes, survey finds
The finding highlights how employer purchasing decisions increasingly favor cheaper benefits over clinical value, pressuring drugmakers' pricing strategies.
Read at Benefits and Pensions Monitor →Full coverage · 5 outlets
- Benefits and Pensions Monitor · lead
- KFFAmericans’ Challenges with Health Care Costs
- Michigan Medicine7 things to know about Medicare’s new GLP-1 coverage
- Center for Medicare AdvocacyMedicare Advantage Industry Blames 2025 Service Cut-Backs on Policy Changes That Hold Them More Accountable
- BritannicaUniversal Health Care | Pros, Cons, Debate, Arguments, Medicare, Medicaid, & Insurance